Every quarter Lumida Wealth presents a visual summary of the 45+ hedge funds we track every quarter that shape the future investing trends.
Enjoy the visual summary below or Check out the full data along with Ram’s insights in spreadsheet format here.
Please note:
– AUM indicates assets under management in managed 13F securities only, the overall AUM due to other positions (Debt, options etc) may be higher.
– Color intensity indicates relative weight.
– Individual stock Rectangles optimized for mobile readability and are not to scale
– Percentages are rounded to nearest decimal and indicate current portfolio weights
– We have prioritized top 5 stock positions wherever available.
– Each manager has a summary, sector analysis and legend for stock information.
Compliance Disclaimer: The information is for general informational purposes only and does not constitute investment advice. Past performance is not indicative of future results, and investments in hedge funds carry risks, including the potential loss of principal. We recommend that you seek independent financial advice before making any investment decisions.
Data Sources: Hedgefollow, Whalewisdom, Lumida analysis
Summary Overview
ADAR1 Capital Management focuses heavily on the healthcare sector, particularly in biotechnology and pharmaceuticals. The fund’s top holdings include significant investments in companies developing innovative therapies, while recent activity shows new investments in emerging biotech firms, alongside reductions in existing biotech positions.
3 sector-specific insights
- The top holdings reflect a strong emphasis on biotechnology, with major investments in companies like Protagonist Therapeutics and Roivant Sciences.
- New investments in emerging biotech firms suggest a strategic interest in innovative therapies and cutting-edge research.
- Reductions in existing biotech holdings indicate a rebalancing or profit-taking strategy.
Top 5 holdings, additions, and reduced positions
- BBIO (BridgeBio Pharma, Inc.): Healthcare sector, focuses on developing transformative medicines to treat genetic diseases.
- BOXX (Boxx Technologies, Inc.): Technology sector, provides high-performance computing systems.
- ROIV (Roivant Sciences Ltd.): Healthcare sector, focuses on developing transformative medicines and technologies.
- CYTK (Cytokinetics, Incorporated): Healthcare sector, develops muscle activators as potential treatments for debilitating diseases.
- PTGX (Protagonist Therapeutics, Inc.): Healthcare sector, develops peptide-based drugs for the treatment of diseases.
New Holdings
- KALA (Kala Pharmaceuticals, Inc.): Healthcare sector, focuses on developing and commercializing therapies for eye diseases.
- INSM (Insmed Incorporated): Healthcare sector, focuses on the development of therapies for patients with serious and rare diseases.
- CRNX (Crinetics Pharmaceuticals, Inc.): Healthcare sector, develops therapies for rare endocrine diseases and endocrine-related tumors.
- PCSC (Processa Pharmaceuticals, Inc.): Healthcare sector, develops drugs to improve the survival and/or quality of life for patients with high unmet medical needs.
- RZLT (Rezolute, Inc.): Healthcare sector, focuses on developing therapies for metabolic and orphan diseases.
Reduced Holdings
- INSM (Insmed Incorporated): Healthcare sector, focuses on the development of therapies for patients with serious and rare diseases.
- QTIB (QT Imaging, Inc.): Healthcare sector, develops advanced imaging technologies.
- CRNX (Crinetics Pharmaceuticals, Inc.): Healthcare sector, develops therapies for rare endocrine diseases and endocrine-related tumors.
- PCSC (Processa Pharmaceuticals, Inc.): Healthcare sector, develops drugs to improve the survival and/or quality of life for patients with high unmet medical needs.
- RZLT (Rezolute, Inc.): Healthcare sector, focuses on developing therapies for metabolic and orphan diseases.
